The Department of Health and Human Services has unfurled a roadmap for aligning its approach to AI adoption in healthcare with the broad AI aspirations of President Trump. 

HHS’s 340B drug discount program is set to shift to a rebate model on New Year’s Day. But a lawsuit and temporary restraining order filed by the AHA and others may block the change from going live on time. 

Will there or won’t there be a federal moratorium on state-level regulation of AI? That’s only one question healthcare stakeholders are asking as 2025’s time begins running out.

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 

The nationwide movement of nurses against AI has received an energy infusion.

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions. 

Semaglutide alters Alzheimer’s biomarkers but doesn’t slow the disease’s advance. 

Some cardiologists feel the specialty is inclusive and nothing needs to change, but not everyone agrees with that sentiment. A new survey detailed the perspective of more than 1,500 cardiologists.